Categories Uncategorized

Study Finds That Focusing on the Past May Worsen Symptoms of Depression

A study recently published in the “Journal of Psychiatric Research” discovered that childhood trauma was linked to higher symptoms of depression, particularly in individuals who demonstrated a tendency to focus on the past instead of the future or even the present. Clinical depression, which is also known as major depressive disorder, is among the most common mental health conditions in the world. Childhood trauma is a typical feature of the disorder.

The authors of the stud — Yingying Wang and colleagues — suggest that a personality factor may play a role in this association between depression and early trauma, noting that an individual’s tendency to focus more on the past than the present as well as the future has been associated with both depressive symptomology and childhood trauma. The researchers sought to investigate whether focusing on the past was a trait that was present before depression set in or was its consequence.

For their study, they recruited almost a hundred patients who suffer from major depressive disorder and nearly 70 subjects who had minimal symptoms of depression or hadn’t been diagnosed with any psychiatric condition. The latter group served as the control population. Each participant was then asked to complete a self-report questionnaire that measured five time perspectives of future, hedonistic present, fatalistic present, negative past and positive past as well as five types of childhood maltreatment. Time perspective refers to an individual’s tendency to orient their thoughts toward the future, present and past.

The researchers discovered that, in comparison with the participants without depression, those who suffered from depression demonstrated a greater tendency toward a fatalistic present perspective and a negative past perspective. In addition to this, they demonstrated a lower tendency toward future perspectives and positive past.

The researchers also found that participants tended to focus more on the past than the future and present if there was more childhood trauma in their past, noting that they demonstrated serious symptoms of depression the more they focused on the past.

To learn whether differences in time perspective emerged with depression or if they were already present before the disorder set in, the researchers then had almost half of the participants go through a five-day therapy that involved their dorsolateral prefrontal cortex being stimulated through transcranial magnetic stimulation. The scientists observed a reduction in symptoms of depression but saw no impact on the participant’s time perspective, which led them to the conclusion that differences in time perspective were present even before symptoms of depression began to manifest.

Not everyone has been benefiting from the existing treatments for depression, possibly because those medicines didn’t address the root cause of the condition. The new class of mental health treatments being developed by companies such as Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) offer patients hope for superior clinical outcomes since the active pharmaceutical ingredients being targeted by these companies often restructure the brain and decrease thought patterns that perpetuate the mental health disease.

NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) are available in the company’s newsroom at https://ibn.fm/CYBN

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Advancing Early Detection, Tackling Heart Disease Through AI and Biomarker Insights

The scale and consequences of cardiovascular disease reinforce why innovation in this space remains essential.…

2 days ago

Study Uncovers Why the Risk of Breast Cancer Increases with Age

New research has mapped how breast tissues change as women age. The findings help to explain why breast…

2 days ago

House Hearing Puts Hospital CEOs on the Spot Over Exorbitant Charges

During a recent House hearing conducted by the Ways and Means Committee, hospital CEOs were put on the…

3 days ago

Study Finds Exercise, Ibuprofen Combat Brain Fog in Cancer Patients

Most cancer patients report cognitive deterioration, such as memory loss and difficulty concentrating as they…

5 days ago

MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Deploying AI for Non-Invasive Intoxication Detection

Voice Analytics and AI to Transform Drug and Alcohol Testing Disseminated on behalf of MindBio Therapeutics…

5 days ago

The Evidence-Interrogation Play: How Oncotelic Therapeutics Inc.’s (OTLC) PDAOAI Platform Fits Pharma’s Broader AI Transformation

Oncotelic’s PDAOAI platform indexes 125,000+ PubMed abstracts on TGF-β signaling, enabling researchers to interrogate the…

5 days ago